We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Middlebrook Pharmaceuticals (MM) | NASDAQ:MBRK | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.1335 | 0 | 01:00:00 |
MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) today announced that James H. Cavanaugh, Ph.D., Martin A. Vogelbaum and Harold R. Werner have resigned from the Company’s Board of Directors effective immediately.
“We thank Jim, Martin and Hal for their contributions to MiddleBrook as Board members,” said Dave Becker, acting president and chief executive officer of MiddleBrook.
About MiddleBrook Pharmaceuticals
MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) currently markets MOXATAG, the first and only FDA-approved once-daily amoxicillin, and KEFLEX (cephalexin, USP), the immediate-release brand of cephalexin. MiddleBrook’s proprietary delivery technology, PULSYS, enables the pulsatile delivery, or delivery in rapid bursts, of certain drugs. For more information about MiddleBrook, please visit www.middlebrookpharma.com.
MiddleBrook, MiddleBrook Pharmaceuticals (stylized), MiddleBrook Pharmaceuticals, Inc., are MiddleBrook’s trademarks and have been registered in the U.S. Patent and Trademark Office or are the subject of pending U.S. trademarks applications. References to “we,” ‘‘us,” “our,” ‘‘MiddleBrook,” or the “Company,” refer to MiddleBrook Pharmaceuticals, Inc., and its subsidiaries.
1 Year Middlebrook Pharmaceuticals (MM) Chart |
1 Month Middlebrook Pharmaceuticals (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions